Literature DB >> 28794884

Unusual presentations of Comamonas kerstersii infection.

M Almuzara1,2, C Barberis1, F Veiga1, R Bakai2, R Cittadini3, C Vera Ocampo3, M Alonso Serena2, E Cohen2, M S Ramirez4, A Famiglietti1, D Stecher5, M Del Castillo3, C Vay1,3.   

Abstract

The association of Comamonas kerstersii with peritonitis resulting from the presence of perforated appendix has previously been described by our research team. In the present study, we describe the isolation of this microorganism from two forms of unusual presentations of C. kerstersii infection not previously described in the literature: localized intra-abdominal infection (psoas abscess) and pelvic peritonitis.

Entities:  

Keywords:  Comamonas kerstersii; pelvic peritonitis; perforated appendix; psoas abscess; unusual presentation

Year:  2017        PMID: 28794884      PMCID: PMC5537401          DOI: 10.1016/j.nmni.2017.07.003

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Introduction

Comamonas spp. are nonfermenting Gram-negative rods originally described in 1985 including a single species, Comamonas terrigena [1]. In 1987, Pseudomonas acidovorans and Pseudomonas testosteroni were later reclassified as members of the genus Comamonas. Subsequently Comamonas acidovorans was reclassified as Delftia acidovorans [2]. The previous single species C. terrigena actually comprises three distinct DNA hybridization groups: Comamonas terrigena, Comamonas aquatica and Comamonas kerstersii [3]. Phenotypic and genotypic differences among these three DNA hybridization groups indicate they are different species: Comamonas terrigena (DNA group 1), Comamonas aquatica (C. terrigena DNA group 2), and Comamonas kerstersii (C. terrigena DNA group 3) [3]. C. kerstersii is a recognized phytopathogen, widely distributed in water, soil and plants, with the ability to survive in aquatic environments, making it an opportunistic pathogen [3]. We have previously described the ability of C. kerstersii to cause perforated-appendix related intra-abdominal infections [4], which had never previously been reported. Here we describe two cases of C. kerstersii infections with unusual clinical presentations: first, a case of a psoas abscess and absence of free fluid in the abdominal cavity in a diabetic patient, and second, a case of pelvic peritonitis (peritonitis resulting from genital tract infection) in a patient with grade IV pelvic inflammatory disease. In addition, we report another 12 clinical cases of intra-abdominal infections by this organism from patients admitted to our hospital.

Material and methods

Clinical specimens were properly collected and processed according to the Manual of Clinical Microbiology [5]. After 48 hours of incubation at 35°C at ambient air temperature, growth of a nonfermenting Gram-negative bacillus was observed in all abdominal cavity cultures. White, smooth colonies with entire edges grew to a diameter of 1.5 mm on blood agar at ambient air temperature. Phenotypic identification of all isolates (n = 14) was performed by conventional biochemical tests [6] and by the scheme proposed by Wauters and Vaneechoutte [7] on the basis of three enzymatic tests, i.e. oxidase, trypsin (benzyl–arginine arylamidase or benzyl–arginine aminopeptidase) and pyrrolidonylaminopeptidase. Additionally, other biochemical tests, such as determination of acid production from glucose, colistin susceptibility, desferrioxamine susceptibility, urease production, motility, nitrate reduction, growth at 42°C and tyrosine hydrolysis, were required to reach final identification. C. kerstersii strain 25 (GenBank accession no. KC714047) was used as a control strain for phenotypic identification studies. In addition, identification by matrix-assisted desorption ionization–time of flight mass spectrometry (MALDI-TOF MS; Bruker Daltonics, Bremen, Germany) was carried out. Phenotypic identification was confirmed with molecular identification (amplification and subsequent sequencing of the gyrB gene (coding for subunit beta of DNA gyrase) using the primers described by Tayeb et al. [8]. Antibiotic susceptibility test was performed using the VITEK 2 System using the AST-082 panel (gram negative susceptibility card). The minimum inhibitory concentration results were interpreted using Clinical and Laboratory Standards Institute categories [9].

Case 1

A 54-year-old woman with a history of obesity, hypertension and diabetes was admitted to the intensive care unit with septic shock. She developed diabetic ketoacidosis with polyphagia, polydipsia and polyuria and progressive sensory deterioration until 2 days before hospital admission. A peripheral venous blood sample taken at admission had the following laboratory findings: white blood cell count, 32 300/mm3 (normal range, 3500/mm3 to 10 500/mm3); haematocrit, 42% (normal range, 38–46%); haemoglobin count, 11.5 g/dL (normal range, 12.3–15.3 g/dL); and platelet count, 268 000/mm3 (normal range, 150 000/mm3 to 450 000/mm3). An arterial blood gas test revealed pH 7.09, partial CO2 pressure 20.1 mm Hg, partial O2 pressure 71.0 mm Hg, HCO3 concentration 6 mmol/L, 82.8% O2 saturation and a −22 mEq/L base excess—parameters consistent with metabolic acidosis. The serum biochemistry results were as follows: [Na], 127 mEq/L; [K], 2.4 mEq/L; blood urea nitrogen level, 60 mg/dL; creatinine level, 8.5 mg/dL; and glycemia, 627 mg/dL. Her husband told us that 15 days before admission the patient had experienced lumbosacral pain, for which she consulted different medical institutions and received different analgesic treatments. A 14 by 89 mm heterogeneous collection was found in the left parietocolic space by abdominal ultrasound. However, the abdominal cavity was free of fluid. An abdominal computed tomographic scan revealed a left psoas abscess. Percutaneous drainage was performed, which resulted in our obtaining abundant purulent material, which was sent for culture. Empirical treatment with piperacillin/tazobactam 4.5 g iv every 8 hours and vancomycin 1 g iv every 12 hours was started for a 14-day period. C. kerstersii with Escherichia coli and Bacteroides fragilis growth was observed in the culture. The antibiotic treatment scheme was changed to trimethoprim/sulfamethoxazole 15 mg/kg (based on the trimethoprim component) iv/12 hours and metronidazole 500 mg iv/8 hours for 30 days. The patient's response was favourable, and she was therefore discharged.

Case 2

A 15-year-old female patient was assisted at a healthcare centre in the suburbs with an abdominal pain episode of 72 hours of progress associated with vomiting and fever in the last 12 hours. Symptomatic treatment was indicated. As a result of the persistence and worsening of the signs and symptoms, she consulted the Hospital de Clínicas Emergency Room, where she was found to be seriously ill and febrile, with abdominal splinting. The admission diagnosis was acute surgical abdomen. The peripheral venous blood sample taken at admission had the following laboratory findings: white blood cell count, 14 000/mm3; haematocrit, 42%; haemoglobin count, 14.2 g/dL; and platelet count, 330 000/mm3. Her serum biochemistry results were as follows: [Na], 137 mEq/L; [K], 3.5 mEq/L; blood urea nitrogen level, 16 mg/dL; creatinine level, 8.2 mg/dL; and glycemia 113 mg/dL. Because perforated appendicitis was suspected, the consulting paediatric surgeon performed an emergency laparoscopy. During the exploratory laparoscopy examination, purulent four-quadrant peritonitis was observed, but appendicitis or bowel perforation could not be confirmed. The appendix was intact; therefore, no appendectomy was performed. Instead, an erythematous, congestive and enlarged (5 × 3 cm) right fallopian tube coated with fibrin as well as inflamed ovaries were observed, so right salpingectomy was performed. Peritoneal fluid and two salpingectomy samples were taken for culture. A drainage tube was placed in the Douglas pouch. C. kerstersii, E. coli, Streptococcus anginosus and B. fragilis grew in the peritoneal fluid sample and in both salpingectomy samples. The patient received antibiotic treatment with ceftriaxone (2 g/day iv, 6 days), metronidazole (500 mg/12 hours by mouth, 8 days) and doxycycline (100 mg/12 hours by mouth, 8 days), completing a 14-day treatment with amoxicillin/clavulanic acid 500 mg/8 hours by mouth. After completing the antibiotic course, and as a result of a favourable clinical progress, she was discharged from hospital.

Other cases

In 12 other patients in the 2010–2015 period, C. kerstersii was isolated from the abdominal fluid of patients with diagnosed acute peritonitis. In most of them (n = 10), it was the result of a gangrenous appendix or perforated appendicitis (Table 1). In all cases, C. kerstersii was isolated with accompanying flora. Patients were 18 to 84 years old. The clinical progress of all patients was favourable (Table 1).
Table 1

Clinical and microbiologic characteristics of patients with secondary peritonitis due to Comamonas kerstersii

Case no.Age (years)/SexClinical presentationUnderlying diseasePredisposing conditionIdentified pathogensAntibiotic treatmentProgress
136, FAbdominal pain, nausea, vomitingNo underlying diseaseGangrenous appendicitis, purulent peritonitisBacteroides fragilis, Comamonas kerstersiiAmpicillin, ampicillin/sulbactam, piperacillin-tazobactamFavourable
261, MAbdominal pain, febrile syndromeNo underlying diseaseGangrenous acute appendicitis, acute peritonitisEscherichia coli, C. kerstersiiPiperacillin/tazobactamFavourable
340, MAbdominal pain, febrile syndrome, vomitingNo underlying diseaseGangrenous, acute appendicitis, acute generalized peritonitisE. coli, C. kerstersiiCeftriaxone, ornidazoleFavourable
438, FAbdominal pain, febrile syndromeNo underlying diseaseAcute appendicitis, pelvic abscessE. coli, C. kerstersiiCiprofloxacin, metronidazoleFavourable
518, FAbdominal pain, fever, nausea, vomitingNo underlying diseaseGangrenous acute appendicitis with perforated base, generalized peritonitisStreptococcus viridans group, C. kerstersiiPiperacillin/tazobactam, ampicillin/sulbactamFavourable
621, FAbdominal pain, febrile syndromeNo underlying diseaseGangrenous appendicitis, purulent peritonitisCitrobacter amalonaticus, C. kerstersiiCeftriaxone, ornidazoleFavourable
784, MAbdominal pain, febrile syndromeNo underlying diseasePerforated appendicitisE. coli, C. kerstersiiCeftriaxone, ornidazoleFavourable
832, MFever, retroperitoneal haematomasmoking, inhalational drugsFirearm wound; colon perforation, faecal peritonitis, interloop abscessesStreptococcus anginosus, C. kerstersiiPiperacillin/tazobactam, vancomycin, colistin + drainageFavourable
919, MAcute abdomenNo underlying diseasePerforated appendicitis, peritonitis appendicularE. coli, C. kerstersiiAmpicillin, gentamicin, metronidazoleFavourable
1035, MAbdominal painNo underlying diseasePeritonitis appendicularE. coli, C. kerstersiiCiprofloxacin, metronidazoleFavourable
1167, MAcute abdomenGlioblastoma multiforme, hypertension, mitral valve surgeryPurulent peritonitis resulting from perforated sigmoidE. coli, S. viridans group; B. fragilis, C. kerstersiiAmpicillin/sulbactam, amoxicillin/clavulanate acid after oral + colostomyFavourable
1263, MAbdominal painDiabetes, dyslipidemia, obesityDiverticulum, appendicular purulent peritonitisE. coli, C. kerstersiiCiprofloxacin, metronidazoleFavourable
Clinical and microbiologic characteristics of patients with secondary peritonitis due to Comamonas kerstersii In all 14 cases, spectral scores between 2021 and 2145 for C. kerstersii were obtained by MALDI-TOF MS. Additionally, gyrB gene sequences analysis revealed 99% identity with the gyrB sequence of Comamonas kerstersii (GenBank accession no. KC714047). The minimum inhibitory concentration ranges (expressed in μg/mL) of C. kerstersii isolates were as follows: ampicillin ≤2 to 32; Ampicillin/sulbactam (AMS) ≤2 to ≤2; cephalothin ≤2 to ≤2; piperacillin/tazobactam ≤4 to ≤4; cefotaxime ≤1 to 4; ceftazidime ≤1 to 8; cefepime ≤1 to 4; imipenem ≤0.25 to 0.5; meropenem ≤0.25 to 0.25; amikacin ≤2 to 16; gentamycin ≤1 to 4; ciprofloxacin ≤0.25 to 2; Trimethoprim-sulfamethoxazole (TMS) ≤2 to 16; colistin ≤0.5 to 16.

Discussion

In 2013 we described the association of C. kerstersii isolation from free liquid in the abdominal cavity with the presence of perforated appendix [4]. Other authors have reported new cases of intra-abdominal infections due to perforated appendix [10]. These findings suggest that infections caused by C. kerstersii could be underestimated because the identification of isolates using only conventional phenotypic methods does not allow accurate determination of the genus. In previously published cases of Comamonas infection, the identification of isolates was only achieved by phenotypic methods, which do not allow differentiation among species of genera [11], [12], [13], [14], [15], [16], [17]. In this work, we highlight the isolation of this species from a localized intra-abdominal infection: a psoas abscess of potential renal origin in a diabetic patient (patient 1). In a series of 42 cases of psoas abscesses studied by Wong et al. [18], the most common causative organism for a primary psoas abscess was methicillin-susceptible Staphylococcus aureus, while for abscesses originating in the gastrointestinal or urinary tract it might be polymicrobial [18], [19], [20], [21]. In this type of infections, E. coli was usually the most common organism [19], [21]. Other organisms—including Bacteroides spp., Peptostreptococcus spp., Streptococcus viridans group and Enterococcus faecalis—were also reported [18], [19], [20], [21]. To date C. kerstersii has not yet been described as being involved in the cause of psoas abscess. In the second case we describe here, the peritonitis infection might have ascended from the vagina through the fallopian tubes because this patient had salpingitis [22], [23]. This source of infection has been described in a previously healthy 31-year-old woman [24]. Salpingitis involves inflammation of the fallopian tube. It usually presents as acute abdomen, and because appendicitis usually includes the same symptoms, salpingitis diagnosis may be delayed until the appendix is surgically explored [25]. Salpingitis, mainly reported in sexually active women, is usually caused by sexually transmitted microorganisms, such as Neisseria gonorrhoeae and Chlamydia trachomatis [26], although other microorganisms that colonize the lower genital tract can ascend to the endometrium, producing endometritis, salpingitis and peritonitis. The polymicrobial aetiology of acute salpingitis has been well documented [26], [27], showing that anaerobes (Peptostreptococcus and Bacteroides spp.), Enterobacteriaceae (E. coli) and aerobic streptococci are the most frequently isolated microorganisms [26], [27]. Moreover, infrequent microorganisms like Edwardsiella tarda [28] and Plesiomonas shigelloides [29] have also been implicated in salpingitis. However, to our knowledge, the isolation of C. kerstersii has not previously been reported in this type of infection. In addition, the isolation of C. kerstersii from the stool of patients with gastroenteritis (seven cases; data not shown) indicates potential intestinal carriage resulting from environmental exposure (i.e. water or food). Other authors have also proposed water as the source of intestinal infection [30], [31]. Biswas et al. [10] reported the isolation of C. kerstersii from the faecal samples of 27 patients with diarrhoea, suggesting that the environmental exposure leading to the intestinal carriage may be more common than most commonly supposed. In our previous study, we pointed out the isolation of C. kerstersii from peritonitis resulting from perforated appendix; in this work, we highlight the isolation of this microorganism from peritonitis resulting from salpingitis and from a localized intra-abdominal infection (psoas abscess). The presence of a nonfermentating Gram-negative rod in the abdominal cavity of a patient with intestinal perforation should raise suspicion of C. kerstersii. Also, C. kerstersii isolation from abscesses broadens the spectrum of infections caused by this microorganism.
  25 in total

1.  Streptococcus pneumoniae peritonitis secondary to genital tract infection in a previously healthy woman.

Authors:  J Gómez Rodrigo; B Padilla; A Delgado-Iribarren; J L Dargallo; C Pedroviejo; J Elviro
Journal:  Clin Infect Dis       Date:  1992-12       Impact factor: 9.079

Review 2.  Iliopsoas abscess--a review and update on the literature.

Authors:  D Shields; P Robinson; T P Crowley
Journal:  Int J Surg       Date:  2012-09-05       Impact factor: 6.071

Review 3.  Two cases of bacteremia due to an unusual pathogen, Comamonas testosteroni in Iran and a review literature.

Authors:  Shohreh Farshad; Fatemeh Norouzi; Maneli Aminshahidi; Behzad Heidari; Abdolvahab Alborzi
Journal:  J Infect Dev Ctries       Date:  2012-06-15       Impact factor: 0.968

Review 4.  Bacteremia due to Comamonas species possibly associated with exposure to tropical fish.

Authors:  Marcus D Smith; Jeremy D Gradon
Journal:  South Med J       Date:  2003-08       Impact factor: 0.954

5.  Comparative phylogenies of Burkholderia, Ralstonia, Comamonas, Brevundimonas and related organisms derived from rpoB, gyrB and rrs gene sequences.

Authors:  Lineda Ait Tayeb; Martine Lefevre; Virginie Passet; Laure Diancourt; Sylvain Brisse; Patrick A D Grimont
Journal:  Res Microbiol       Date:  2007-12-24       Impact factor: 3.992

6.  Retrospective review of clinical presentations, microbiology, and outcomes of patients with psoas abscess.

Authors:  O F Wong; P L Ho; S K Lam
Journal:  Hong Kong Med J       Date:  2013-04-22       Impact factor: 2.227

7.  Phylogenetic relationships among members of the Comamonadaceae, and description of Delftia acidovorans (den Dooren de Jong 1926 and Tamaoka et al. 1987) gen. nov., comb. nov.

Authors:  A Wen; M Fegan; C Hayward; S Chakraborty; L I Sly
Journal:  Int J Syst Bacteriol       Date:  1999-04

8.  Pseudomonas testosteroni infections: eighteen recent cases and a review of the literature.

Authors:  D J Barbaro; P A Mackowiak; S S Barth; P M Southern
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

9.  Bacteremia caused by Comamonas kerstersii in a patient with diverticulosis.

Authors:  Onya Opota; Barbara Ney; Giorgio Zanetti; Katia Jaton; Gilbert Greub; Guy Prod'hom
Journal:  J Clin Microbiol       Date:  2013-12-26       Impact factor: 5.948

10.  Description of Comamonas aquatica comb. nov. and Comamonas kerstersii sp. nov. for two subgroups of Comamonas terrigena and emended description of Comamonas terrigena.

Authors:  Georges Wauters; Thierry De Baere; Anne Willems; Enevold Falsen; Mario Vaneechoutte
Journal:  Int J Syst Evol Microbiol       Date:  2003-05       Impact factor: 2.747

View more
  6 in total

1.  Complete genome sequencing of Comamonas kerstersii 8943, a causative agent for peritonitis.

Authors:  Xiawei Jiang; Wenhong Liu; Beiwen Zheng
Journal:  Sci Data       Date:  2018-11-06       Impact factor: 6.444

2.  First report of Comamonas kerstersii causing urinary tract infection.

Authors:  M Almuzara; R Cittadini; M L Estraviz; A Ellis; C Vay
Journal:  New Microbes New Infect       Date:  2018-03-20

3.  Utility of platforms Viteks MS and Microflex LT for the identification of complex clinical isolates that require molecular methods for their taxonomic classification.

Authors:  María Florencia Rocca; Rubén Barrios; Jonathan Zintgraff; Claudia Martínez; Lucía Irazu; Carlos Vay; Mónica Prieto
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

4.  Does the endometrial cavity have a molecular microbial signature?

Authors:  Andrew D Winters; Roberto Romero; Maria Teresa Gervasi; Nardhy Gomez-Lopez; Maria Rosa Tran; Valeria Garcia-Flores; Percy Pacora; Eunjung Jung; Sonia S Hassan; Chaur-Dong Hsu; Kevin R Theis
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

5.  Comamonas kerstersii Bacteremia of Unknown Origin.

Authors:  Kassie Rong; Johan Delport; Fatimah AlMutawa
Journal:  Case Rep Infect Dis       Date:  2022-03-27

6.  Maternal peripartum bacteremia caused by intrauterine infection with Comamonas kerstersii: A case report.

Authors:  Hai Qu; Yi-Hong Zhao; Wen-Mei Zhu; Lu Liu; Ming Zhu
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.